News

Jerusalem, Israel, January 24, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has filed infringement complaints against a number of finished dose companies which manufacture sertraline hydrochloride, AB rated to Zoloft®, and their active pharmaceutical ingredient suppliers. Teva filed the complaints in the United States District Courts of New Jersey, Delaware, Southern District New York, and Maryland for infringement of its U.S. Patents Nos. 6,600,073 (expiring June 2020), 6,500,987 (expiring November 2019), 6,495,721 (expiring May 2020) and 6,897,340 (expiri Read More »

Jerusalem , Israel, January 30, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' Focalin™ (Dexmethylphenidate Hydrochloride) Tablets, 2.5 mg, 5 mg, and 10 mg. As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.Teva's AB-rated Dexmethylphenidate HCl Tablets are indicated for the treatment of atte Read More »

Conference Call Scheduled For 8:45 Am Et Company To Host Marketsite Event On February 21, 2007Jerusalem, Israel, February 4, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its fourth quarter 2006 financial results on Tuesday, February 13, 2007. The earnings release will be available on Teva's web site at www.tevapharm.com.Teva will host a conference call and live webcast on that same day, at 08:45AM ET to discuss its fourth quarter 2006 results and overall business environment. A Question & Answer session will follow this discussion. Investor Read More »

Jerusalem, Israel, February 11, 2007 - Further to the company's announcement of October 18, 2006, Mr. Shlomo Yanai will assume the role of President & Chief Executive Officer of Teva Pharmaceutical Industries Ltd. on March 1, 2007. Mr. Shlomo Yanai will succeed Mr. Israel Makov who served as President and Chief Executive Officer for the past five years. For the past few months, Mr. Yanai has been studying the company as part of the CEO transition process with the outgoing President & CEO, Mr. Israel Makov. Mr. Yanai met with management teams and employees of the group's manufacturing a Read More »

Jerusalem, Israel,, February 13, 2007 - *Quarterly Net Sales of $2.3 Billion, up 63%; Annual Net Sales of $8.4 Billion, Up 60%*U.S. GAAP Quarterly EPS of $0.56; U.S. GAAP Annual EPS of $0.69*Adjusted Quarterly EPS of $0.53, up 18%; Annual Adjusted EPS of $2.30, up 45%*Cash Flow from Operations: Quarterly $765 Million; Annual $2,058 MillionNet sales for the fourth quarter of 2006 increased 63% to $2,277 million, compared to $1,401 million in the fourth quarter of 2005. The main contributors to the growth in sales for the quarter were the inclusion of Ivax sales, which benefited all regions, and Read More »

Jerusalem, Israel, March 1, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) for Alprazolam Extended Release Tablets, 0.5 mg, 1 mg, 2 mg and 3 mg. Shipment of this product will begin immediately. Teva's product is the AB-rated equivalent of Pharmacia and Upjohn's Xanax® XR Tablets, a product indicated for treatment of panic disorder.Total annual sales of this product, including brand and generic sales, are approximately $54 million, based on IMS sal Read More »

Jerusalem, Israel, March 5, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has reached an agreement with Biovail Corporation regarding Bupropion Hydrochloride Extended-Release Tablets ("Bupropion HCl ER tablets"), the generic version of the antidepressant Wellbutrin XL® Tablets, for the United States market. The agreement, following U.S. Federal Trade Commission review, resolves litigation between Teva's supplier of the 300 mg product, IMPAX Laboratories, Inc. (NASDAQ:IPXL) and Biovail involving a patent which expires in 2018. The agreement also rel Read More »

Jerusalem, Israel, March 6, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA)announced today that it will continue to sell its generic version of OxyContin® tablets at least through the end of 2007. In October 2006, Teva settled a patent dispute with the Purdue Frederick Company and certain of its affiliates pertaining to Teva's generic version of Purdue's OxyContin® (oxycodone HCl extended-release) tablets. The settlement provided a full release of Teva and its distributors, purchasers and patients and requires Teva to cease sales of the product upon the occurrence of certain continge Read More »

Jerusalem, Israel, March 8, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA)announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) for Cabergoline Tablets, 0.5 mg.Shipment of the product will begin immediately.Teva's Cabergoline Tablets are the AB-rated generic equivalent of Pharmacia & Upjohn's Dostinex® Tablets, a product indicated for treatment of hyperprolactinemic disorders.Total annual sales of this product in the U.S., including brand and generic sales,are approximately $74 million, based on Read More »

Jerusalem, Israel, March 11, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA)announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDAfor Moexipril HCland HydrochlorothiazideTablets, 7.5 mg/12.5 mg, 15 mg/12.5 mg and 15 mg/25 mg. Shipment of these products will begin immediately.Teva's Moexipril HCl and Hydrochlorothiazide Tablets are the first AB-rated generic equivalent of Schwarz Pharma's Uniretic® Tablets, a product indicated for the treatment of hypertension.The brand product had annual sales of approx Read More »